Scarica l'app Stockscreener
1.17
4.88%
-0.06
Dopo l'orario di chiusura:
1.14
-0.03
-2.56%
NanoViricides Inc Borsa (NNVC) Ultime notizie
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
NNVC’s price-to-cash ratio: Is it a good investment at the moment? - US Post News
NanoViricides seeks to eliminate treatment delays with its broad spectrum antiviral NV-387 - Proactive financial news
NanoViricides warns of bird flu pandemic as outbreak spreads in Massachusetts - Proactive Investors UK
NanoViricides (NYSE:NNVC) Trading Down 1.8% – What’s Next? - Defense World
NanoViricides to present at MicroCap Conference 2025 in Atlantic City - Proactive Investors UK
Game-Changing Antiviral Drug Shows 'Superior Results' Against Multiple Viruses$10B Market Potential - StockTitan
NanoViricides advances antiviral drug with Phase II Clinical trial to Combat MPox - Proactive Investors USA
NanoViricides taps clinical research organization for Phase II trial of NV-387 - Proactive Investors UK
NanoViricides Engages CRO for Phase II Clinical Trial - Oil City Derrick
NanoViricides to present antiviral drug pipeline at Biotech Showcase 2025 - Proactive Investors Australia
NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025 - Oil City Derrick
NanoViricides CEO discusses NV-387’s broad spectrum promiseICYMI - Proactive Investors Australia
NanoViricides highlights urgent need for broad-spectrum antiviral solutions amid viral threats - Proactive Investors Australia
Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals - AccessWire
NanoViricides (NYSE:NNVC) Trading Down 5% – Should You Sell? - Defense World
First US bird flu fatality raises alarms over mutations in H5N1 virus - Proactive Investors USA
NanoViricides CEO discusses groundbreaking broad-spectrum antiviral treatment - Proactive Investors UK
NanoViricides, Inc. Files Quarterly ReportReports a Strong Cash Position Sufficient for Initial C - AOL
NanoViricides sees NV-387 as a key defense against bird flu pandemic - Proactive Investors UK
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape - Oil City Derrick
NanoViricides' NV-387 Shows Breakthrough 88% Survival Rate Against H5N1 Bird Flu in Key Study - StockTitan
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America By Proactive Investors - Investing.com UK
NanoViricides CEO highlights urgency of H5N1 preparedness as cases rise in North America - Proactive Investors UK
NanoViricides: Pioneering the Future of Antiviral Therapies - TechBullion
NanoViricides (AMEX:$NNVC) Leads Innovation In Broad-Spectrum Antiviral Therapies - Barchart
NanoViricides (AMEX:$NNVC) Leads Innovation in Broad-Spectrum Antiviral Therapies - openPR
NanoViricides (NYSE:NNVC) Rating Lowered to “Sell” at StockNews.com - Defense World
NanoViricides pushes NV-387 to Phase II trials - Proactive Investors Australia
NanoViricides' Antiviral Drug NV-387 Advances to Phase II Trials Amid Funding Needs - StockTitan
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical TrialMultiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID - Source ONE News
NanoViricides Inc (NNVC) Quarterly 10-Q Report - Quartz
NanoViricides pushes NV-387 to Phase II trials | NYSE-A:NNVC - Proactive Investors USA
NanoViricides: Fiscal Q1 Earnings Snapshot - San Antonio Express-News
NanoViricides to update on broad-spectrum antiviral drug at Spartan Capital Investors Conference - Proactive Investors Australia
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am - Oil City Derrick
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference - Proactive financial news
NanoViricides President Dr. Diwan to Present at the PODD Conference - News-Press Now
NanoViricides exec to showcase breakthrough antiviral technology at PODD Conference | NYSE-A:NNVC - Proactive Investors USA
Can NanoViricides Inc (NNVC) Stock Rise to the Top of Healthcare Sector Tuesday? - InvestorsObserver
Interview with the President and Executive Chairman: NanoViricides, Inc. (NYSEAMERICAN:NNVC) - The Wall Street Transcript
NNVC - Insider Financial
Chronic Fatigue Syndrome Market Demand and Opportunities - openPR
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology - Oil City Derrick
Renaissance Technologies LLC Boosts Position in NanoViricides, Inc. (NYSE:NNVC) - Defense World
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy - Insider Monkey
7 Best Nanotech Penny Stocks to Buy - Insider Monkey
1.03%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):